Downregulation of TAP1 and TAP2 in early stage breast cancer
暂无分享,去创建一个
A. Nassar | K. Knutson | Bahaaeldin Youssef | A. Henle | Danell Puglisi-Knutson | Andrea M Henle | Andrea M. Henle
[1] N. Angelopoulos,et al. Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer , 2015, Breast Cancer Research and Treatment.
[2] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[3] F. Mami-Chouaib,et al. TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor‐specific cytotoxic T lymphocytes , 2013, Annals of the New York Academy of Sciences.
[4] C. Horbinski,et al. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer , 2012, Cancer Immunology, Immunotherapy.
[5] P. Validire,et al. Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL , 2011, The Journal of Immunology.
[6] T. van Hall,et al. Strategies to counteract MHC-I defects in tumors. , 2011, Current opinion in immunology.
[7] R. Ferris,et al. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes , 2011, Cancer Immunology, Immunotherapy.
[8] M. Einstein,et al. Genetic Variants in TAP Are Associated with High-Grade Cervical Neoplasia , 2009, Clinical Cancer Research.
[9] J. Tao,et al. Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity. , 2008, The Journal of investigative dermatology.
[10] R. Gopaul,et al. Combining the Antigen Processing Components TAP and Tapasin Elicits Enhanced Tumor-Free Survival , 2008, Clinical Cancer Research.
[11] Wilfred A. Jefferies,et al. Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas , 2007, Molecular and Cellular Biology.
[12] B. Seliger,et al. Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1. , 2007, Vaccine.
[13] W. Jefferies,et al. TAP expression reduces IL‐10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma , 2007, International journal of cancer.
[14] R. Tampé,et al. Modulation of the antigen transport machinery TAP by friends and enemies , 2006, FEBS letters.
[15] W. Jefferies,et al. Using the TAP Component of the Antigen-Processing Machinery as a Molecular Adjuvant , 2005, PLoS pathogens.
[16] B. Seliger,et al. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. , 2005, Cancer research.
[17] Ronald Simon,et al. Tissue microarrays for early target evaluation. , 2004, Drug discovery today. Technologies.
[18] Robert Tampé,et al. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. , 2004, Physiology.
[19] M. van de Rijn,et al. Applications of microarrays to histopathology , 2004, Histopathology.
[20] M. Ressing,et al. Bovine herpesvirus 1 interferes with TAP-dependent peptide transport and intracellular trafficking of MHC class I molecules in human cells , 2003, Archives of Virology.
[21] S. Ferrone,et al. A Single-nucleotide Deletion Leads to Rapid Degradation ofTAP-1 mRNA in a Melanoma Cell Line* , 2003, The Journal of Biological Chemistry.
[22] Anneliese Schimpl,et al. HIV Type 1 Abrogates TAP-Mediated Transport of Antigenic Peptides Presented by MHC Class I , 2002 .
[23] M. Matsui,et al. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon‐γ , 2002, Journal of gastroenterology and hepatology.
[24] H. Moch,et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.
[25] Holger Moch,et al. Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology? , 2001, Advances in anatomic pathology.
[26] K. Wright,et al. Loss of Interferon-γ Inducibility of TAP1 and LMP2 in a Renal Cell Carcinoma Cell Line , 2000 .
[27] G. Blair,et al. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins , 2000, Oncogene.
[28] Wilfred A. Jefferies,et al. TAP expression provides a general method for improving the recognition of malignant cells in vivo , 2000, Nature Biotechnology.
[29] S. Hinkley,et al. An Early Pseudorabies Virus Protein Down-Regulates Porcine MHC Class I Expression by Inhibition of Transporter Associated with Antigen Processing (TAP) , 2000, The Journal of Immunology.
[30] M. Sy,et al. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. , 1998, Cancer research.
[31] D. Hicklin,et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. , 1998, Cancer research.
[32] D. Hicklin,et al. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. , 1996, Tissue antigens.
[33] R. Tampé,et al. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer , 1996, Nature Genetics.
[34] A. Harris,et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. , 1996, British Journal of Cancer.
[35] A. Harris,et al. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. , 1995, Cancer research.
[36] A. Harris,et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. , 1994, The American journal of pathology.
[37] C. Meijer,et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. , 1994, British Journal of Cancer.
[38] C. Meijer,et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas , 1994, The Journal of experimental medicine.
[39] Robert Tampé,et al. The transporter associated with antigen processing: function and implications in human diseases. , 2002, Physiological reviews.
[40] O. Kutsch,et al. HIV type 1 abrogates TAP-mediated transport of antigenic peptides presented by MHC class I. Transporter associated with antigen presentation. , 2002, AIDS research and human retroviruses.
[41] K. Wright,et al. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. , 2000, Cancer research.
[42] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.